The pathophysiological basis for intensive insulin replacement (original) (raw)
Polonsky KS, Given BD, Hirsch LJ, Hartmut T, Shapiro ET, Beebe C, Frank BH, Galloway JA, van Cauter E . Abnormal pattern of insulin secretion in non-insulin-dependent diabetes mellitus. N Eng J Med 1988; 318: 1231–1239. ArticleCAS Google Scholar
Del Prato S . Loss of early insulin secretion leads to postprandial hyperglycemia. Diabetologia 2003; 46 (Suppl 1): M2–M8. ArticleCASPubMed Google Scholar
Polonsky KS, Sturis J, Graeme I . Seminars in medicine of the Beth Israel Hospital, Boston: non-insulin dependent diabetes mellitus—a genetically programmed failure of the beta-cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777–783. ArticleCASPubMed Google Scholar
Kahn SE . The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3–19. ArticleCASPubMed Google Scholar
Weyer C, Bogardus C, Mott DM, Pratley RE . The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type II diabetes mellitus. J Clin Invest 1999; 104: 787–794. ArticleCASPubMedPubMed Central Google Scholar
Van Haeften T, Pimenta W, Mitrakou A, Korytkowski M, Jenssen T, Yki-Jarvinen H, Gerich JE . Relative contributions of B-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 2000; 49: 1318–1325. ArticleCASPubMed Google Scholar
UK Prospective Diabetes Study Group. verview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–1258.
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA . Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004; 47: 31–39. ArticleCASPubMed Google Scholar
Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR . Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabetic Med 1998; 15: 290–296. ArticleCASPubMed Google Scholar
Porte D . Banting lecture 1991. Beta-cells in type II diabetes mellitus. Diabetes 1991; 40: 166–180. ArticlePubMed Google Scholar
Gerich JE . Clinical significance, pathogenesis, and management of post-prandial hyperglycemia. Arch Int Med 2003; 163: 1306–1316. ArticleCAS Google Scholar
Bonora E, Muggeo M . Postprandial blood glucose as a risk factor for cardiovascular disease in type 2 diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107–2114. ArticleCASPubMed Google Scholar
Ceriello A . The possible role of postprandial hyperglycaemia in the pathogenesis of diabetes complications. Diabetologia 2003; 46 (Suppl 1): M9–M16. ArticleCASPubMed Google Scholar
Erlinger T, Brancati F . Postchallenge hyperglycemia in a national sample of US adults with type 2 diabetes. Diabetes Care 2001; 24: 1734–1738. ArticleCASPubMed Google Scholar
Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J . Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22–29. ArticleCASPubMed Google Scholar
Kloppel G, Mattias L, Habich K, Oberholzer M, Heitz PU . Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985; 4: 110–125. CASPubMed Google Scholar
Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC . Islet amyloid, increased alpha cells, reduced beta-cells and exocrine fibrosis; quantitative changes in pancreas in type-2 diabetes. Diabetes Res 1988; 9: 151–160. CASPubMed Google Scholar
Sakuraba H, Mitzukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S . Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002; 45: 85–96. ArticleCASPubMed Google Scholar
Rahier J, Goebbels RM, Henquin JC . Cellular composition of the human diabetic pancreas. Diabetologia 1983; 24: 366–371. ArticleCASPubMed Google Scholar
Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger RH . Quantification of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 1982; 31: 694–700. ArticleCASPubMed Google Scholar
Butler AE, Janson J, Bonner-Wier S, Ritzel R, Rizza R, Butler PC . [beta]-cell deficit and increased [beta]-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102–110. ArticleCASPubMed Google Scholar
Kaiser N, Leibowitz G, Nesher R . Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16: 5–22. ArticleCASPubMed Google Scholar
Bonner-Weir S . Islet growth and development in the adult. J Mol Endocrinol 2000; 24: 296–302. Article Google Scholar
DCCT Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: a randomized, controlled trial. Ann Intern Med 1998; 128: 517–523.
Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill T . Beneficial effect of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231–2237. ArticleCASPubMed Google Scholar
Robertson RP, Olson LK, Zhang H . Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 1994; 43: 1085–1089. ArticleCASPubMed Google Scholar
Krauss S, Zhang C, Scorrano L, Dalgaard LT, St-Pierre J, Grey ST, Lowell BB . Superoxide-mediated activation of uncoupling protein 2 causes pancreatic B cell dysfunction. J Clin Invest 2003; 112: 1831–1842. ArticleCASPubMedPubMed Central Google Scholar
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall M-A . Basal-bolus therapy with insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin in patients with type 1 diabetes. Diabetologia 2004; 47: 622–629. ArticleCASPubMed Google Scholar
Vague P, Selam JL, Svein S, de Leeuw I, Elte JWF, Haahr H, Kristensen A, Draeger E . Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590–595. ArticleCASPubMed Google Scholar